A randomized, single dose, open label, four-period, two-sequence, full-replicate, cross-over oral bioequivalence study between the test product, Rifapentine 150 mg Tablets (Cipla Ltd., India) and the reference product, PRIFTINÃ?Â® (rifapentine 150 mg) Tablets (Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807), after administration of one tablet in healthy adult human subjects under fed conditions. - 21-11-268

Cipla Ltd India0 个研究点目标入组 40 人开始时间: 待定最近更新: 2022年10月17日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•Healthy willing adult human volunteers should have:
•an age between 18 to 45 years (both inclusive), having body mass index (BMI) between 18.5 and 30 kg/m2, weighing not less than 45 kg
•no medical history of significant diseases
•a physical examination, laboratory evaluations that are clinically not significant
•a negative or non-reactive Rapid Plasma Reagin (RPR), Hepatitis B Surface Antigen (HBsAg), Hepatitis C (Anti HCV), antibodies to human immuno-deficiency Virus (HIV) I and II
•negative urine alcohol test
•negative urine test for drugs of abuse
•negative urine pregnancy test for females
•negative test for COVID-19 [Real Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) or Rapid antigen test]
•normal or clinically not significant chest X-ray
•vital signs examinations that are within clinically not significant limits
•no medical complaints

排除标准

•Volunteers will be excluded based on the following criteria:
•1.Volunteers who have history of known hypersensitivity to rifamycin or related class of drug.
•2.Volunteers having difficulty in swallowing tablet.
•3.Volunteers with history of a known food allergy.
•4.Volunteers who have vital signs abnormalities (systolic blood pressure less than 100 or greater than 140 mm of Hg or diastolic blood pressure less than 60 or greater than 90 mm of Hg or pulse rate less than 50 beats per minute or more than 100 beats per minute) during pre-study screening and vital signs examination before check-in.
•5.Volunteers having any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract.
•6.Volunteers who have history of severe cutaneous adverse reactions such as Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms syndrome.
•7.Volunteers who have recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study check-in.
•8.Volunteers who have clinically significant signs and symptoms or history of respiratory, cardiovascular, gastrointestinal, dermatological, neurological, psychiatric, genitourinary, endocrinological, musculoskeletal, bleeding disorder, tumor/ cancer, eye, ear, nose and throat disease.
•9.Volunteers who have suffered any clinically significant illness in the 2 weeks prior to dosing or who have been hospitalized within 3 months preceding the start of the study.
•10.Volunteers who have taken any drug that induces/inhibits the hepatic microsomal enzymes within 30 days prior to dosing.
•11.Volunteers who have taken any prescription medication or over-the-counter products available (including vitamins and products from natural origin such as ayurvedic, unani, siddha and homeopathic medicines) and topical medication meant for systemic absorption, within the 7 days prior to dosing.
•12.Volunteers who have depot injection or an implant of any drug within 3 months prior to dosing.
•13.Volunteers who have a history of difficulty in donating blood.
•14.Volunteers who have donated blood (1 unit or 350 mL) within 90 days prior to dosing.
•15.Volunteers who have history of porphyria.
•16.Volunteers who have taken any investigational product or participated in any drug research study requiring blood donation within 90 days prior to dosing.
•17.Volunteers who have unsuitable veins for repeated venipuncture, evidence of skin lesions on forearm or signs of venipuncture on the forearm suggestive of recent blood donation or participation in a study.
•18.Female volunteers who have clinically significant signs and symptoms or history of gynaecological disease.

研究者

发起方

Cipla Ltd India

相似试验

进行中（未招募）

1 期

Bioavailability of Methylcobalamin Sublingual tablet 1500 mcg in healthy human volunteers.

CTRI/2015/09/006176Troikaa Pharmaceuticals Ltd12

进行中（未招募）

1 期

Randomized, open-label, single dose, four-period, cross-over drug-drug interaction study comparing reference products Crestor 20 mg film coated tablets, Norvasc 10 mg tablets and Tritace 10 mg tablets administrated concomitantly versus each drug administrated alone in healthy male and female subjects under fasting conditions.ot applicable (submitted trial is a study in healthy subjects).MedDRA version: 20.0Level: PTClassification code: 10020772Term: Hypertension Class: 100000004866

CTIS2023-505153-41-00Adamed Pharma S.A.60

已完成

不适用

A Randomized, Open-label, Single-dose, Four-sequence, Four -period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix OcasDiseases of The genitoruinary system

KCT0001363Chonbuk National University Hospital36

Unknown

1 期

Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerSimvastatin, Bioequivalence Study, Healthy Thai Volunteer

TCTR20230301002International Bio Service Co., Ltd.44

已完成

不适用

A randomized, open-label, multiple dose, four-way crossover pharmacodynamic equivalence study comparingOrlistat 60mg and 120mg hard gelatin capsules in healthyvolunteers.

CTRI/2011/12/002292aboratorios Liconsa SA60